Subscribe

Shitanshu Uppal

SOLO-3: Olaparib vs. Chemotherapy in PSROC

Olaparib significantly improved PFS and ORR over nonplatinum chemotherapy, though no OS benefit was observed in the overall population. In patients with ≥3 prior therapies, chemotherapy had more favorable OS.

Question of the Day 05-21-25

Which of the following best characterizes the drug-to-antibody ratio (DAR)

Publications Update # 102

Happiest country, PDS Vs. NACT a fresh perspective (video), fear in the OR, and a vulvar cancer review article worth reading.

Vulvar Cancer Quiz

Publications Update # 101

Interview with Isabel Allende, updated tips for staying organized for the board prep, p53 staining in endometrial cancer, secondary debulking in platinum-sensitive ovarian cancer, Epigenetic MLH1 and outcomes

Publications Update # 100

Unreasonable hospitality, mini-tutorial juvenile granulosa cell tumor, when to make a protective stoma in ovarian cancer, NRG-GY023 trial, finding the ureter and RSO surgical technique and a review paper on HGSOC

NRG-GY023: Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab

The addition of durvalumab with olaparib and cediranib did not improve PFS in platinum-resistant ovarian cancer patients with prior bevacizumab exposure.

One Hundred Posts: GYOEDU Website Updates

Publications Update # 99

Managing perfectionism, conization prior to open radical hysterectomy, KELIM score in ovarian cancer with mini-video tutorial

Welcome to GYOEDU

Hi there! 🌟 As a valued member of the GYOEDU community,